Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

Tariff-Free Relocation to the US

Tariff-Free Relocation to the US

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

Eisai and Alzheon Explore Encouraging Outcomes in Alzheimer’s High-Risk Patient Group

Eisai and Alzheon Explore Encouraging Outcomes in Alzheimer’s High-Risk Patient Group

At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4, who were identified in trials as being at higher risk of brain bleeds while on the treatment. Alzheon, meanwhile, added further detail to trial results of its candidate in patients with the same genetic profile.

Key Takeaways from the Committee for Medicinal Products for Human Use (CHMP) Meeting Held from March 23 to 26, 2026

Five new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended five medicines for approval at its March 2026 meeting.The committee recommended…, CHMP statistics Key figures from the March 2026 CHMP meeting are represented in the graphic below. , CHMP statistics:…, Positive recommendations on new medicines, Adstiladrin INN nadofaragene firadenovec  Marketing authorisation applicant Ferring Pharmaceuticals A/S Therapeutic indication Treatment of adult…, Imdylltra INN tarlatamab Marketing authorisation applicant Amgen Europe B.V Therapeutic indication Treatment of extensive-stage small cell lung cancer. More…, Joenja INN leniolisib  Marketing authorisation applicant Pharming Technologies B.V. Therapeutic indication Treatment of activated phosphoinositide 3-…, Zepzelca INN lurbinectedin Marketing authorisation applicant Pharma Mar S.A. Therapeutic indication Maintenance treatment of adult patients with extensive-…, Positive recommendations on new hybrid medicines, Bopediat INN furosemide  Marketing authorisation holder Proveca Pharma Limited Therapeutic indication Treatment of all conditions requiring diuresis due…, Positive recommendations on extensions of therapeutic indications , Besponsa INN inotuzumab ozogamicin Marketing authorisation holder Pfizer Europe MA EEIG More information Besponsa : pending EC decision, Capvaxive INN pneumococcal polysaccharide conjugate vaccine (21-valent) Marketing authorisation holder Merck Sharp & Dohme B.V.  More information…, Feraccru INN ferric maltol Marketing authorisation holder Norgine B.V. More information Feraccru : pending EC decision, Hetronifly INN serplulimab Marketing authorisation holder Accord Healthcare S.L.U. More information Hetronifly: pending EC decision (EMA/VR/0000284402)…, Hympavzi INN marstacimab Marketing authorisation holder Pfizer Europe MA EEIG More information Hympavzi : pending EC decision, Imcivree INN setmelanotide Marketing authorisation holder Rhythm Pharmaceuticals Netherlands B.V. More information Imcivree : pending EC decision, Lojuxta INN lomitapide Marketing authorisation holder Chiesi Farmaceutici SpA More information Lojuxta : pending EC decision, Mekinist INN trametinib Marketing authorisation holder Novartis Europharm Limited More information Mekinist : pending EC decision (EMAVR0000271728)Mekinist…, Mresvia INN respiratory syncytial virus mRNA vaccine (nucleoside modified) Marketing authorisation holder Moderna Biotech Spain, S.L. More information…, Namuscla INN mexiletine hcl Marketing authorisation holder Lupin Europe GmbH More information Namuscla : pending EC decision, Retsevmo INN selpercatinib Marketing authorisation holder Eli Lilly Nederland B.V. More information Retsevmo : pending EC decision, Sotyktu INN seucravacitinib  Marketing authorisation holder Bristol-Myers Squibb Pharma EEIG More information Sotyktu : pending EC decision, Tafinlar INN dabrafenib Marketing authorisation holder Novartis Europharm Limited More information Tafinlar : pending EC decision (EMAVR0000271728)Tafinlar…, Outcome of re-examination, Hetlioz INN tasimelteon  Marketing authorisation holder Vanda Pharmaceuticals Netherlands B.V. More information Hetlioz, Withdrawal of application, Blarcamesine Anavex INN blarcamesine  Marketing authorisation applicant Anavex Germany GmbH Therapeutic indication Treatment of Alzheimer’s disease…, Referral procedures, Tecovirimat SIGA INN tecovirimat More information Tecovirimat SIGA , Other updates, Sarclisa INN isatuximab Marketing authorisation holder Sanofi Winthrop Industrie More information Sarclisa : pending EC decision, Reflection paper on a tailored clinical approach in biosimilar developmentAdopted…

Is It Possible for Electrical Stimulation to Regain Vision?

Is It Possible for Electrical Stimulation to Regain Vision?

The optic nerve is like a high-speed fiber-optic cable between your eyes and your brain. But once that cable is cut, whether through trauma or disease, the nerve cannot be repaired and vision cannot be restored.

Some engineers are working to change that.

Shadi Dayeh, a professor of electrical and computer engineering at UC San Diego, has been developing a technology that could electrically stimulate and regenerate the optic nerve. His work is part of a multidisciplinary initiative called VISION (Viability, Imaging, Surgical, Immunomodulation, Ocular preservation, and Neuroregeneration) Strategies for Whole-Eye Transplant. The project aims to make vision-restoring, whole-eye transplantation a reality.

While whole-eye transplantation was first achieved in 2023, the procedure cannot yet restore sight. Dayeh wants to make whole-eye transplantation “not only anatomically viable but also neurophysiologically useful,” he says. If he succeeds, transplant recipients will actually be able to see out of their new eye.

“The optic nerve is the main highway between the eye and the brain. It’s also one of the hardest pathways to repair,” Dayeh says. “So, from an engineering point of view, it’s a major challenge and a major opportunity.”

But before they can reconnect the optic nerve to the brain, Dayeh’s team first has to understand how these two parts of our bodies communicate. Recently, the team completed what Dayeh calls “a foundational step:” mapping how changes in light, color, and frequency affect the visual axis, from the retina to the optic nerve and the brain.

Learning a visual language

The optic nerve is small, but mighty.

An average adult’s optic nerve is only about 4.5 to 5 centimeters long and roughly 0.5 centimeter wide. But a cross-section of the optic nerve holds over a million axons, the threadlike projections of nerve cells that conduct electrical impulses.

“The optic nerve is very small and delicate,” Sayeh says. “It’s a densely packed cable that carries an enormous information bandwidth—probably the densest bandwidth cable in our nervous system.”

To understand exactly how this delicate cable transmits visual information, Dayeh’s team has developed biocompatible electrode arrays that wrap around the optic nerve and sit on the visual cortex (the part of the brain that processes visual information) in animal and cadaver studies.

The arrays send electrical pulses across the visual pathway, from the optic nerve to the brain, and record the eye’s and brain’s responses to electrical and visual stimulation. This means the team can see how the optic nerve reads certain visual signals—such as changes in light, color, and contrast—how the optic nerve sends these messages to the brain, and how the brain interprets them.

“It’s like a distributed set of sensors in a communication system,” Dayeh says.

As the technology collects high-resolution data, the team maps the optic nerve and visual cortex to understand what Dayeh calls “the language of the visual pathway”—how visual signals get encoded in the optic nerve and represented in the visual cortex. “The idea is not just to record, but to build a code book across the visual pathway.”

The optic nerve isn’t a straight, uniform cylinder. Its diameter varies along its curving structure. That’s why Dayeh’s team developed electrode arrays that are ultrathin and flexible, ensuring stable placement, “like an electronic skin on the surface of the neural tissue,” Dayeh says.

Adding to the difficulty is the very tricky matter of charging optic and brain tissue. “The visual system is not like a muscle that you can electrically shock and then see what happens,” Dayeh says.

To avoid heating the tissue, Dayeh’s system maintains careful control of the density and spatial spread of the electrical charges. “The thermal load is very important for safety,” he says. “Much of our earlier engineering work went into electrode materials and geometries that can inject charge effectively and safely.”

Regenerating the optic nerve

Understanding the visual pathway’s language is one piece of a larger puzzle. Now that they have successfully mapped optic nerve and visual cortex signals, Dayeh’s team is investigating how their technology can help a severed optic nerve regenerate.

To that end, the electrode interface technology very precisely applies and records controlled, localized electrical stimulations to the optic nerve in order to determine where and how much stimulation can spur regeneration.

“The stimulation is not a magic switch,” Dayeh explains. “It’s a precision tool that assists and accelerates the biological processes of regenerating the neural pathway.”

Dayeh’s work contributes to several efforts aimed at restoring sight, which he considers “one of the most ambitious challenges in regenerative medicine and neurotechnology.” While Dayeh’s team measures, maps, and potentially guides the reconnection between the eye and the brain, other approaches include neuroprotection, or preserving the vision cells and circuits before they’re lost, and visual prosthetics and neural byass systems, which restore sight by delivering information directly to the retina, optic nerve, or visual cortex when the natural pathway cannot function.

Dayeh cautions that optic nerve regeneration is a developing field, and much is as yet unknown. Still, research has shown that, when active, cells can survive longer and can better integrate with surrounding tissue. Dayeh’s technology activates cells electrically. “In a simple sense,” he says, “our goal is to activate the cells so they survive longer.”

For now, optic-nerve regeneration technology is being tested in animals to show that a cut optic nerve can grow axons to the brain and restore vision. Dayeh anticipates that in perhaps three years, after rigorous tests and studies on the technology’s efficacy and safety, studies of the novel technology could be conducted for the first time in humans.

Moving Past Clichés in Investment Strategies for Longevity

Moving Past Clichés in Investment Strategies for Longevity

In this episode of Denatured, you’ll listen to Sergey Jakimov, managing partner at LongeVC and Artem Trotsyuk, operating partner, US, LongeVC. We speak about how developers in the longevity space should stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly tackle age-related conditions.

Exploring Indiana’s Thriving Life Sciences Sector Beyond the Cornfields

Exploring Indiana’s Thriving Life Sciences Sector Beyond the Cornfields

With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its mark. The president and CEO of the Indiana Life Sciences Association discusses the sector’s upside, challenges and where it’s headed in the future.